8-K Announcements
6Material company update
Mar 3, 2026·SEC
Material company update
Feb 10, 2026·SEC
Material company update
Jan 6, 2026·SEC
China Pharma Holdings, Inc.(CPHI)Earnings, Financials & Key Ratios
CPHI•AMEX
Price updated Jun 19, 2026
SectorHealthcareIndustrySpecialty & Generic PharmaSub-IndustryLarge-scale generic drug manufacturers
AboutChina Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People's Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate and Ozagrel Sodium to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. It also provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. In addition, the company offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Further, it provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. The company offers its products through distributors, as well as through its network of 16 sales offices and approximately 1,000 sales representatives. China Pharma Holdings, Inc. was founded in 1993 and is based in Haikou, the People's Republic of China.Show more
- Revenue$4M-8.5%
- EBITDA-$2M+23.4%
- Net Income-$3M+32.7%
- EPS (Diluted)-0.74-174.1%
- Gross Margin-3.18%+92.7%
- EBITDA Margin-36.42%+16.3%
- Operating Margin-74.53%+26.4%
- Net Margin-76.91%+26.5%
- ROE0%+100.0%
CPHI Key Insights
China Pharma Holdings, Inc. (CPHI) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Share count reduced 75.4% through buybacks
✗Weaknesses
- ✗Sales declining 17.5% over 5 years
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when CPHI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CPHI Price & Volume
China Pharma Holdings, Inc. (CPHI) stock price & volume — 10-year historical chart
Loading chart...
CPHI Growth Metrics
China Pharma Holdings, Inc. (CPHI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-14.71%
5 Years-17.53%
3 Years-20.03%
TTM-7.07%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM22.36%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM14.43%
Return on Capital
10 Years-21.21%
5 Years-30.39%
3 Years-28.16%
Last Year0%
CPHI Recent Earnings
China Pharma Holdings, Inc. (CPHI) EPS & revenue vs analyst estimates — last 4 quarters
Q2 2026Latest
May 15, 2026Metric
Actual
Est
EPS
$0.04
—
Rev
$983.5B
—
Q2 2026
Apr 1, 2026Metric
Actual
Est
EPS
$0.04
—
Rev
$1M
—
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.17
—
Rev
$756,217
—
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$0.16
—
Rev
$1M
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $0.04 | $983.5B |
| Q2 2026 | Apr 1, 2026 | $0.04 | $1M |
| Q4 2025 | Nov 12, 2025 | $0.17 | $756,217 |
| Q3 2025 | Aug 14, 2025 | $0.16 | $1M |
Based on last 12 quarters of dataView full earnings history →
CPHI Peer Comparison
China Pharma Holdings, Inc. (CPHI) competitors in Large-scale generic drug manufacturers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 CHNR | 41.53M | 4.30 | -88.11 | -15.72% | ||||
 CNET | 3.27M | 1.00 | -1.49 | -70.11% | -33.27% | -28.25% | 0.04 | |
 SGBX | 32.96K | 0.96 | -0.00 | -69.88% | -5.69% | -134.41% | ||
 SIGA | 309.85M | 4.32 | 13.09 | -31.8% | 21.61% | 10.62% | 0.00 | |
 HROW | 1.6B | 42.87 | -306.21 | 36.41% | -5.57% | -33.92% | 4.84 | |
 LXRX | 892.83M | 2.01 | -14.36 | 60.24% | -37.46% | -18.64% | 0.58 | |
 NUVB | 1.93B | 5.56 | -9.27 | 6.99% | -102.06% | -44.1% | 0.03 | |
 CASI | 2.33M | 0.15 | -0.06 | -15.77% | -183.93% | -301.8% | 11.96 |
Compare CPHI vs Peers
China Pharma Holdings, Inc. (CPHI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CPHI Income Statement
China Pharma Holdings, Inc. (CPHI) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 13.21M | 12.33M | 10.92M | 10.87M | 9.64M | 8.1M | 7.01M | 4.53M | 4.14M | 3.99M |
Revenue Growth % | -15.15% | -6.67% | -11.41% | -0.53% | -11.27% | -15.95% | -13.48% | -35.41% | -8.49% | -7.07% |
Cost of Goods Sold | 10.74M | 10.36M | 9.44M | 8.91M | 9.29M | 8.6M | 7.29M | 6.51M | 4.28M | 4.53M |
COGS % of Revenue | 81.32% | 83.98% | 86.43% | 82.03% | 96.38% | 106.09% | 104.01% | 143.84% | 103.18% | - |
Gross Profit | 2.47M▲ 0% | 1.97M▼ 20.0% | 1.48M▼ 24.9% | 1.95M▲ 31.8% | 349.27K▼ 82.1% | -493.92K▼ 241.4% | -281.08K▲ 43.1% | -1.99M▼ 606.4% | -131.95K▲ 93.4% | -535.68K▲ 0% |
Gross Margin % | 18.68% | 16.02% | 13.57% | 17.97% | 3.62% | -6.09% | -4.01% | -43.84% | -3.18% | -13.42% |
Gross Profit Growth % | -23.3% | -20% | -24.95% | 31.76% | -82.12% | -241.41% | 43.09% | -606.42% | 93.35% | - |
Operating Expenses | -21.15M | -12.42M | 4.87M | 4.53M | 3.21M | 3.06M | 2.47M | 2.6M | 2.96M | 3.06M |
OpEx % of Revenue | -160.07% | -100.74% | 44.6% | 41.7% | 33.29% | 37.7% | 35.24% | 57.48% | 71.34% | - |
Selling, General & Admin | 5.48M | 5.17M | 4.64M | 4.04M | 3.15M | 2.96M | 2.25M | 2.31M | 2.83M | 2.73M |
SG&A % of Revenue | 41.48% | 41.9% | 42.49% | 37.16% | 32.63% | 36.56% | 32.04% | 51.08% | 68.22% | - |
Research & Development | 90.47K | 172.38K | 229.64K | 377.96K | 318.96K | 185.86K | 240.08K | 283.94K | 280.9K | 335.08K |
R&D % of Revenue | 0.68% | 1.4% | 2.1% | 3.48% | 3.31% | 2.29% | 3.42% | 6.27% | 6.78% | - |
Other Operating Expenses | 4.83T | 0 | 0 | 115.19K | -255.22K | -93.85K | -15.76K | 5.7K | -151.56K | 872 |
Operating Income | -4.5M▲ 0% | -3.97M▲ 11.7% | -3.39M▲ 14.6% | -2.58M▲ 23.9% | -2.86M▼ 10.9% | -3.55M▼ 24.1% | -2.75M▲ 22.5% | -4.59M▼ 66.8% | -3.09M▲ 32.7% | -3.6M▲ 0% |
Operating Margin % | -34.03% | -32.18% | -31.03% | -23.73% | -29.67% | -43.79% | -39.25% | -101.32% | -74.53% | -90.13% |
Operating Income Growth % | -7.22% | 11.74% | 14.58% | 23.93% | -10.95% | -24.07% | 22.46% | -66.76% | 32.69% | - |
EBITDA | -1.2M | -709.62K | -460.78K | 101.18K | 227.31K | -848.44K | 1.83K | -1.97M | -1.51M | -1.44M |
EBITDA Margin % | -9.12% | -5.75% | -4.22% | 0.93% | 2.36% | -10.47% | 0.03% | -43.52% | -36.42% | -36.15% |
EBITDA Growth % | -8.02% | 41.1% | 35.07% | 121.96% | 124.67% | -473.25% | 100.22% | -107559.11% | 23.41% | 34.87% |
D&A (Non-Cash Add-back) | 3.29M | 3.26M | 2.93M | 2.68M | 3.09M | 2.7M | 2.75M | 2.62M | 1.58M | 2.15M |
EBIT | -18.62M | -10.41M | -20.38M | -2.57M | -2.86M | -3.54M | -2.75M | -4.58M | -3.09M | -3.45M |
Net Interest Income | -474.92K | -412.74K | -294.19K | -288.48K | -538.97K | -423.86K | -327K | -147.5K | -100.03K | -98.96K |
Interest Income | 64.41K | 38.52K | 27.53K | 5.67K | 3.04K | 10.76K | 6.6K | 6.64K | 2K | 1.08K |
Interest Expense | 539.33K | 451.26K | 321.72K | 294.16K | 542K | 434.62K | 333.6K | 154.14K | 102.04K | 100.04K |
Other Income/Expense | -14.66M | -6.89M | -17.31M | -288.48K | -538.97K | -423.86K | -327K | -147.5K | -99.02K | 52.59K |
Pretax Income | -19.15M▲ 0% | -10.86M▲ 43.3% | -20.7M▼ 90.6% | -2.87M▲ 86.2% | -3.4M▼ 18.6% | -3.97M▼ 16.9% | -3.08M▲ 22.5% | -4.74M▼ 53.8% | -3.19M▲ 32.7% | -3.55M▲ 0% |
Pretax Margin % | -144.98% | -88.07% | -189.51% | -26.38% | -35.26% | -49.02% | -43.91% | -104.58% | -76.91% | -88.82% |
Income Tax | 122.63K | -109.99K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | -0.64% | 1.01% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -19.28M▲ 0% | -10.75M▲ 44.2% | -20.7M▼ 92.6% | -2.87M▲ 86.2% | -3.4M▼ 18.6% | -3.97M▼ 16.9% | -3.08M▲ 22.5% | -4.74M▼ 53.8% | -3.19M▲ 32.7% | -3.55M▲ 0% |
Net Margin % | -145.91% | -87.18% | -189.51% | -26.38% | -35.26% | -49.02% | -43.91% | -104.58% | -76.91% | -88.82% |
Net Income Growth % | -109.94% | 44.23% | -92.57% | 86.15% | -18.58% | -16.87% | 22.5% | -53.84% | 32.7% | 22.36% |
Net Income (Continuing) | -19.28M | -10.75M | -20.7M | -2.87M | -3.4M | -3.97M | -3.08M | -4.74M | -3.19M | -3.55M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -4.42▲ 0% | -2.47▲ 44.1% | -4.82▼ 95.1% | -0.72▲ 85.1% | -0.85▼ 18.1% | -1.94▼ 128.2% | -0.29▲ 85.1% | -0.27▲ 6.9% | -0.74▼ 174.1% | -0.83▲ 0% |
EPS Growth % | -109.48% | 44.12% | -95.14% | 85.06% | -18.06% | -128.24% | 85.05% | 6.9% | -174.07% | 14.43% |
EPS (Basic) | -4.42 | -2.47 | -4.82 | -0.72 | -0.85 | -1.94 | -0.29 | -0.27 | -0.74 | - |
Diluted Shares Outstanding | 4.61M | 4.61M | 4.61M | 4.61M | 4.61M | 5.26M | 10.6M | 17.46M | 4.29M | 4.29M |
Basic Shares Outstanding | 4.61M | 4.61M | 4.61M | 4.61M | 4.61M | 5.26M | 10.6M | 17.46M | 4.29M | 4.29M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
CPHI Balance Sheet
China Pharma Holdings, Inc. (CPHI) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 12.29M | 8.75M | 5.58M | 5.32M | 9.09M | 5.96M | 6M | 3.27M | 2.35T | 2M |
Cash & Short-Term Investments | 2.03M | 1.19M | 1.07M | 957.65K | 4.86M | 2.03M | 1.42M | 626.88K | 626.88K | 168.47K |
Cash Only | 2.03M | 1.19M | 1.07M | 957.65K | 4.86M | 2.03M | 1.42M | 626.88K | 626.88K | 168.47K |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 2.46M | 1.09M | 682.01K | 529.54K | 835.4K | 464.45K | 728.31K | 281.07K | 290.67K | 257.92K |
Days Sales Outstanding | 67.85 | 32.18 | 22.79 | 17.79 | 31.62 | 20.92 | 37.91 | 22.65 | 25.6 | 26.33 |
Inventory | 6.41M | 5.05M | 3.59M | 3.71M | 3.34M | 2.95M | 3.73M | 2.27M | 1.62T | 1.5M |
Days Inventory Outstanding | 217.67 | 178.17 | 138.74 | 151.72 | 131.18 | 125.14 | 186.82 | 126.97 | 1000K | 32.68M |
Other Current Assets | 709.8K | 1.27M | 155.66K | 55.97K | 471 | 444.64K | 0 | 0 | 379.87B | 0 |
Total Non-Current Assets | 47.66M | 36.63M | 16.66M | 15.8M | 13.56M | 11.82M | 10.47M | 11.62M | 28.65T | 43.32M |
Property, Plant & Equipment | 23.11M | 18.88M | 16.05M | 15.18M | 12.97M | 9.61M | 6.82M | 4.53M | 4.57T | 4.47M |
Fixed Asset Turnover | 0.57x | 0.65x | 0.68x | 0.72x | 0.74x | 0.84x | 1.03x | 1.00x | 0.00x | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 831.77K | 676.05K | 609.37K | 613.83K | 589.62K | 2.21M | 3.65M | 7.09M | 24.08T | 38.67M |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 180K | 540K |
Other Non-Current Assets | 23.72M | 17.07M | 0 | 0 | 0 | 0 | 0 | 0 | -180K | 0 |
Total Assets | 59.95M▲ 0% | 45.38M▼ 24.3% | 22.24M▼ 51.0% | 21.12M▼ 5.0% | 22.65M▲ 7.3% | 17.78M▼ 21.5% | 16.47M▼ 7.4% | 14.89M▼ 9.6% | 31T▲ 208224343.5% | 45.32M▲ 0% |
Asset Turnover | 0.22x | 0.27x | 0.49x | 0.51x | 0.43x | 0.46x | 0.43x | 0.30x | 0.00x | 0.00x |
Asset Growth % | -23.65% | -24.31% | -51% | -5.02% | 7.25% | -21.48% | -7.39% | -9.6% | 99999900% | 100000134.04% |
Total Current Liabilities | 9.23M | 10.05M | 10.05M | 11.4M | 10.51M | 12.74M | 6.82M | 5.02M | 7.4T | 7.27M |
Accounts Payable | 1.14M | 1.06M | 1.37M | 1.23M | 926.75K | 667.08K | 966.42K | 225.11K | 891.08K | 837.11K |
Days Payables Outstanding | 38.77 | 37.39 | 52.82 | 50.56 | 36.4 | 28.32 | 48.37 | 12.61 | 76.06 | 57.4 |
Short-Term Debt | 3.02M | 3.46M | 4.33M | 6.47M | 7.11M | 8.72M | 3.1M | 2.16M | 71.63B | 3.47M |
Deferred Revenue (Current) | 581.13K | 525.65K | 505.4K | 719.79K | 210.03K | 520.29K | 90.51K | 162.21K | 0 | 260.34K |
Other Current Liabilities | 0 | 0 | 0 | 297.49K | 327.03K | 372.58K | 1.26M | 1.59M | 7.33T | 978.97K |
Current Ratio | 1.33x | 0.87x | 0.56x | 0.47x | 0.86x | 0.47x | 0.88x | 0.65x | 0.32x | 0.28x |
Quick Ratio | 0.64x | 0.37x | 0.20x | 0.14x | 0.55x | 0.24x | 0.33x | 0.20x | 0.10x | 0.07x |
Cash Conversion Cycle | 246.75 | 172.95 | 108.71 | 118.95 | 126.4 | 117.74 | 176.36 | 137.01 | 1000K | 32.68M |
Total Non-Current Liabilities | 7.65M | 5.13M | 2.95M | 1.71M | 6.12M | 754.7K | 2.19M | 2.12M | 859.35B | 851.92K |
Long-Term Debt | 6.92M | 4.36M | 2.15M | 904.23K | 5.25M | 0 | 1.41M | 1.39M | 111.55B | 0 |
Capital Lease Obligations | 0 | 0 | 48.7K | 0 | 44.18K | 0 | 39.91K | 0 | 111.55K | 332.1K |
Deferred Tax Liabilities | 738.17K | 764.37K | 753.44K | 805.56K | 824.41K | 754.7K | 742.11K | 731.2K | 747.8B | 747.81B |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 16.88M | 15.18M | 13M | 13.11M | 16.63M | 13.49M | 9.01M | 7.14M | 8.26T | 8.12M |
Total Debt | 9.93M | 7.82M | 6.62M | 7.43M | 12.49M | 8.76M | 4.63M | 3.59M | 3.59M | 3.56M |
Net Debt | 7.9M | 6.63M | 5.55M | 6.47M | 7.63M | 6.73M | 3.21M | 2.96M | 2.96M | 3.39M |
Debt / Equity | 0.23x | 0.26x | 0.72x | 0.93x | 2.08x | 2.04x | 0.62x | 0.46x | 0.00x | 0.10x |
Debt / EBITDA | - | - | - | 73.42x | 54.94x | - | 2526.73x | - | - | -2.47x |
Net Debt / EBITDA | - | - | - | 63.95x | 33.56x | - | 1750.37x | - | - | -2.35x |
Interest Coverage | -34.52x | -23.07x | -63.35x | -8.75x | -5.27x | -8.14x | -8.23x | -29.73x | -30.24x | -34.45x |
Total Equity | 43.07M▲ 0% | 30.2M▼ 29.9% | 9.24M▼ 69.4% | 8M▼ 13.3% | 6.02M▼ 24.8% | 4.29M▼ 28.7% | 7.45M▲ 73.8% | 7.75M▲ 3.9% | 22.74T▲ 293495431.2% | 37.2M▲ 0% |
Equity Growth % | -26.89% | -29.89% | -69.41% | -13.35% | -24.82% | -28.71% | 73.77% | 3.93% | 99999900% | 100000351.12% |
Book Value per Share | 9.34 | 6.55 | 2.00 | 1.74 | 1.30 | 0.82 | 0.70 | 0.44 | 999999.00 | 8.67 |
Total Shareholders' Equity | 43.07M | 30.2M | 9.24M | 8M | 6.02M | 4.29M | 7.45M | 7.75M | 22.74T | 37.2M |
Common Stock | 43.58K | 43.58K | 43.58K | 45.58K | 47.34K | 74.91K | 10.63K | 32.62K | 15.52B | 40.52K |
Retained Earnings | 5.48M | -5.27M | -25.97M | -28.84M | -32.24M | -36.21M | -39.29M | -44.03M | -47.21T | -48.36M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 13.96M | 11.84M | 11.58M | 12.35M | 12.56M | 11.57M | 11.45M | 11.32M | 11.58T | 12.02M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CPHI Cash Flow Statement
China Pharma Holdings, Inc. (CPHI) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 841.22K | 1.26M | 608.31K | -42.26K | -249.84K | -409.55K | -699.69K | -466.36K | 148.26K | 150.79K |
Operating CF Margin % | 6.37% | 10.19% | 5.57% | -0.39% | -2.59% | -5.05% | -9.98% | -10.3% | 3.58% | - |
Operating CF Growth % | -70.95% | 49.43% | -51.61% | -106.95% | -491.19% | -63.92% | -70.84% | 33.35% | 131.79% | 63.61% |
Net Income | -19.28M | -10.75M | -20.7M | -2.87M | -3.4M | -3.97M | -3.08M | -4.74M | -3.19M | -3.55M |
Depreciation & Amortization | 3.29M | 3.26M | 2.93M | 2.68M | 3.09M | 2.7M | 2.75M | 2.62M | 1.58M | 2.23M |
Stock-Based Compensation | 0 | 0 | 0 | 0 | 15.24K | 78.27K | 0 | 0 | 0 | 0 |
Deferred Taxes | 122.63K | 68.42K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 15.7M | 8.04M | 17.27M | 115.19K | -5.21K | -93.85K | 21.65K | 456.44K | -13.11M | -13.33M |
Working Capital Changes | 1.01M | 642.25K | 1.11M | 29.86K | 51.79K | 878.34K | -396.18K | 1.2M | 14.87M | 14.79M |
Change in Receivables | 51.02K | 99.4K | -1.2M | -733.45K | -545.53K | -170.19K | -938.02K | -197.71K | 13.21M | 13.36M |
Change in Inventory | 1.72M | 688.85K | 2M | 807.59K | 1.01M | 689.1K | -17.06K | 1.61M | 589.76K | 680.63K |
Change in Payables | -2.05M | -16.44K | 324.18K | -214.01K | -332.78K | -187.73K | 312.05K | -733.92K | 650.31K | 259.6K |
Cash from Investing | -136.48K | -51.15K | -136K | -867.31K | -438.06K | -401.96K | -11.52K | -291.72K | -137.25K | -56.29K |
Capital Expenditures | -136.48K | -51.15K | -136K | -867.31K | -438.06K | -401.96K | -11.52K | -38.41K | -59.32K | -50.97K |
CapEx % of Revenue | 1.03% | 0.41% | 1.24% | 7.98% | 4.54% | 4.96% | 0.16% | 0.85% | 1.43% | 1.28% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -253.31K | -77.93K | -5.31K |
Cash from Financing | -1.48M | -1.98M | -1.73M | 624.18K | 4.6M | -1.77M | 73.14K | 27.35K | -294.03K | -303.32K |
Debt Issued (Net) | -1.48M | -1.98M | -1.73M | 624.18K | 4.6M | -1.55M | 73.14K | 27.35K | -294.03K | -296.53K |
Equity Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 0 | 0 | 0 | 0 | -223.01K | 0 | 0 | 0 | -6.79K |
Net Change in Cash | -635.59K▲ 0% | -843.63K▼ 32.7% | -1.28M▼ 51.2% | -227.23K▲ 82.2% | 3.9M▲ 1816.9% | -2.83M▼ 172.5% | -606.13K▲ 78.6% | -796.96K▼ 31.5% | -281.77K▲ 64.6% | -244.21K▲ 0% |
Free Cash Flow | 704.74K▲ 0% | 1.21M▲ 71.1% | 472.31K▼ 60.8% | -909.57K▼ 292.6% | -687.89K▲ 24.4% | -811.51K▼ 18.0% | -711.2K▲ 12.4% | -758.08K▼ 6.6% | 11.01K▲ 101.5% | 134.49K▲ 0% |
FCF Margin % | 5.33% | 9.78% | 4.32% | -8.37% | -7.13% | -10.01% | -10.14% | -16.74% | 0.27% | 3.37% |
FCF Growth % | -73.92% | 71.11% | -60.83% | -292.58% | 24.37% | -17.97% | 12.36% | -6.59% | 101.45% | 143.15% |
FCF per Share | 0.15 | 0.26 | 0.10 | -0.20 | -0.15 | -0.15 | -0.07 | -0.04 | 0.00 | 0.03 |
FCF Conversion (FCF/Net Income) | -0.04x | -0.12x | -0.03x | 0.01x | 0.07x | 0.10x | 0.23x | 0.10x | -0.05x | -0.04x |
Interest Paid | 525.79K | 588.19K | 299.16K | 237.53K | 218.23K | 141.8K | 92.44K | 86.77K | 0 | 20.59K |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CPHI Key Ratios
China Pharma Holdings, Inc. (CPHI) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -37.81% | -29.34% | -104.99% | -33.25% | -48.49% | -77.08% | -52.43% | -62.31% | 0% | -0% |
Return on Invested Capital (ROIC) | -5.7% | -6.78% | -9.85% | -13.22% | -15.26% | -21.58% | -19.04% | -32.2% | 0% | -0% |
Gross Margin | 18.68% | 16.02% | 13.57% | 17.97% | 3.62% | -6.09% | -4.01% | -43.84% | -3.18% | -13.42% |
Net Margin | -145.91% | -87.18% | -189.51% | -26.38% | -35.26% | -49.02% | -43.91% | -104.58% | -76.91% | -88.82% |
Debt / Equity | 0.23x | 0.26x | 0.72x | 0.93x | 2.08x | 2.04x | 0.62x | 0.46x | 0.00x | 0.10x |
Interest Coverage | -34.52x | -23.07x | -63.35x | -8.75x | -5.27x | -8.14x | -8.23x | -29.73x | -30.24x | -34.45x |
FCF Conversion | -0.04x | -0.12x | -0.03x | 0.01x | 0.07x | 0.10x | 0.23x | 0.10x | -0.05x | -0.04x |
Revenue Growth | -15.15% | -6.67% | -11.41% | -0.53% | -11.27% | -15.95% | -13.48% | -35.41% | -8.49% | -7.07% |
Related:CPHI Dividend History·CPHI Revenue History·CPHI Price History·CPHI P/E History·CPHI Financial Ratios·CPHI Institutional Holders
CPHI SEC Filings & Documents
China Pharma Holdings, Inc. (CPHI) SEC filings — annual & quarterly reports (10-K, 10-Q)
CPHI Frequently Asked Questions
China Pharma Holdings, Inc. (CPHI) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
China Pharma Holdings, Inc. (CPHI) reported $4.0M in revenue for fiscal year 2025. This represents a 10547% increase from $0.0M in 2002.
China Pharma Holdings, Inc. (CPHI) saw revenue decline by 8.5% over the past year.
China Pharma Holdings, Inc. (CPHI) reported a net loss of $3.5M for fiscal year 2025.
Dividend & Returns
China Pharma Holdings, Inc. (CPHI) has a return on equity (ROE) of 0.0%. Negative ROE indicates the company is unprofitable.
China Pharma Holdings, Inc. (CPHI) generated $0.1M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.